Latest News for: gri

Edit

Eilis O’Hanlon: Does it really matter if The Salt Path is factually accurate? That’s the one question this gri

Irish Independent 17 Dec 2025
.
Edit

GRI Bio Announces Closing of $8.0 Million Public Offering (Form 8-K) (Gri Bio Inc)

Public Technologies 12 Dec 2025
GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, ...
Edit

Notice of Effectiveness (Form EFFECT) (Gri Bio Inc)

Public Technologies 12 Dec 2025
) UNITED STATES. SECURITIES AND EXCHANGE COMMISSION. Washington, D.C. 20549 ... GRI Bio, Inc ... Gri Bio Inc.
Edit

GRI Bio Announces Closing of $8.0 Million Public Offering

Nasdaq Globe Newswire 12 Dec 2025
GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, ...
Edit

Material Agreement (Form 8-K) (Gri Bio Inc)

Public Technologies 12 Dec 2025
) Item 1.01 Entry Into a Material Definitive Agreement. Securities Purchase Agreement. On December 11, 2025, GRI Bio, Inc ... Each Share or Pre-Funded Warrant was sold together with one Series F Warrant to purchase one share of Common Stock ... Gri Bio Inc.
Edit

Kraft Heinz 2025 GRI Content Index (The Kraft Heinz Company)

Public Technologies 12 Dec 2025
) GRI INDEX. The Kraft Heinz Company reports this information with reference to the Global Reporting Initiative (GRI) Standards for the fiscal year ending December 28, 2024. Disclosure. Description. FY2024 Response. General Disclosures. 2-1 ... 2-2 ... 2-3 ... 2-4 ... 20.
Edit

Supplemental Prospectus (Form 424B4) (Gri Bio Inc)

Public Technologies 12 Dec 2025
resources to our planned activities, particularly as we conduct our clinical trials of GRI-0621 and GRI-0803, advance our discovery programs and continue our product development efforts.
Edit

GRI Bio Announces Pricing of $8,000,000 Million Public Offering

Nasdaq Globe Newswire 11 Dec 2025
GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune ...
Edit

GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

Nasdaq Globe Newswire 10 Dec 2025
Study met its primary endpoint demonstrating that GRI-0621 was well tolerated over 12 weeks of treatment, with no drug-related severe or serious adverse events and no increase in GI issues when used with existing approved treatments ... .
Edit

GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) (Form 8-K) (Gri Bio Inc)

Public Technologies 10 Dec 2025
GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune ...
Edit

GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis ("IPF") (Gri Bio Inc)

Public Technologies 10 Dec 2025
GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune ...
Edit

Amendment to Initial Registration Statement (Form S-1/A) (Gri Bio Inc)

Public Technologies 10 Dec 2025
GRI BIO, INC ... GRI Bio, Inc ... GRI Bio, Inc ... Form of Senior Secured Note of GRI Bio Operations, Inc ... GRI Bio, Inc ... GRI Bio Operations, Inc ... Employment Agreement, by and between GRI Bio Operations, Inc ... GRI BIO, INC ... Gri Bio Inc.
Edit

Material Event (Form 8-K) (Gri Bio Inc)

Public Technologies 08 Dec 2025
GRI Bio, Inc. (the "Company") has received topline data from the Phase 2a GRI-0621-IPF-02 clinical trial evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis ("IPF") ... Gri Bio Inc.
Edit

Supplemental Prospectus (Form 424B3) (Gri Bio Inc)

Public Technologies 08 Dec 2025
Our Common Stock is listed on The Nasdaq Capital Market under the symbol "GRI." On December 2, 2025, the last reported sale price of our Common Stock was $1.95 per share ... GRI BIO, INC ... GRI ... GRI Bio, Inc ... December 8, 2025 GRI BIO, INC.
Edit

Initial Registration Statement (Form S-1) (Gri Bio Inc)

Public Technologies 08 Dec 2025
Before we can generate any revenue from sales of our lead product candidate, GRI-0621, GRI-0803 or any of our other product candidates, we must undergo additional clinical development, regulatory review and approval in one or more jurisdictions.

Article Search

tools
×
×
×
×